Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 12 December 2024

Created: 12 December 2024

Last Updated: 12 December 2024

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares…

Posted: 2024-12-12 04:54:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related Bing News Search Results

Press Release: BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering - Newscast

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Thu, 24 Apr 2025 17:00:00 GMT PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...

BriaCell's Bria-OTS shows sustained success against breast cancer

Thu, 24 Apr 2025 08:37:00 GMT BriaCell Therapeutics (TSX:BCT), a Canadian biotechnology stock developing cancer immunotherapies, announced the resolution of the lung metastasis first reported in February in a 78-year-old woman ...

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Wed, 23 Apr 2025 00:31:00 GMT PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical ...

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Tue, 22 Apr 2025 23:29:00 GMT Detailed price information for Briacell Therapeutics Corp WT (BCTXW-Q) from The Globe and Mail including charting and trades.

BriaCell announces ongoing Phase 3 study enrolled over 75 patients

Tue, 22 Apr 2025 04:37:00 GMT Therapeutics announces that its ongoing Phase 3 clinical study has consented over 100 and has enrolled over 75 patients.